Confirmation lcxu

ConFirmaTion

WITNESS OF SIGNATURE document the signing acknowledge client the heard or document this sign nt clie named above the witnessed I DATE REPRESENTATIVE IZED AUTHOR OR CLIENT OF SIGNATURE Colorado. of State the of that not and responsibility my is attendants my by work poor or care poor from results that illness or injury any that understand I work. for up show to fails or late is attendant an when as such support, attendant back-up arrange and emergencies for plan a Develop 19. records. employment maintain and paperwork all manage and Complete 18. CDASS. from termination and/or prosecution, criminal penalties, administrative in result may statements false or misrepresentation that Understand 17. FMS. the to reported immediately are misrepresentations any that and way any in altered not are submitted timesheets Ensure 16. wages. Attendant the in changes any make to FMS the Authorize 15. reimbursement. attendant for timelines established the by FMS to timesheets attendant approved submit and Review 14. services. CDASS providing spent time actual reflect shall Timesheets signatures. attendant and client/AR and completeness, worked, time of accuracy for statements and timesheets attendant all Review 13. www.colorado.gov/hcpf resources. financial of stewardship sound demonstrating while serve we people the for omes outc and access care health improve to is mission Our 866-678-6789 Fax: 866-234-2345 Tel: free: toll call may professionals health nd a consumers Reaction, Adverse an report To 613-957-0335 Fax: or 613-957-0337 Tel: 0K9 K1A Ontario, Ottawa, 0701C Locator: Address CANADA HEALTH Directorate Products Health Marketed Program Vigilance Canada to: reported be also can reaction adverse suspected Any dsscan@its.jnj.com 767-5865 (866) Fax: or 567-3331 (800) Tel: 1L9 M3C Ontario Toronto, Drive Belt Green 19 Department Safety Drug Inc. Janssen-Ortho of division a Tibotec, addresses: following the at Canada Health or Tibotec to reported be should INTELENCE receiving patients in reactions adverse unexpected or serious other or reactions, hypersensitivity or reactions skin serious of case Any treatments. product health with associated risks the underestimate to presumed generally are reactions adverse marketing post- reported spontaneously of basis the on ed determin rates Reporting them. reporting consumers and professionals healthcare on depends reactions adverse -related product health marketed Managing INTELENCE. for Monograph Product Canadian the in information safety new this incorporate to Canada Health with working currently is Tibotec therapy. continued on weeks 1-2 within resolved generally Rash 4. Week after infrequent was and therapy of week second the in ily primar occurred moderate, to mild was rash general, In INTELENCE. with development clinical during subjects of 0.1% < in reported were multiforme erythema and reaction, hypersensitivity severe syndrome, Stevens-Johnson (9.0%). rash was studies 3 Phase the in severity in 2 Grade least at of (ADR) reaction drug adverse reported frequently most The